Phase I Study of Replication-competent

[CANCER RESEARCH 62, 4968–4976, September 1, 2002]. Phase I .... The costs of publication of this article were defrayed in part by the payment of pa...

3 downloads 0 Views 676KB Size

Recommend Documents

Oct 13, 2006 - the adaptation and evaluation of the SFP10–14 ... Twenty-one percent of pupils ... 15–19 years are 16 times more likely to die than those of a ...

liters/h/m2 (n = 6; P < 0.002), denoting a departure from linear pharma- cokinetic behavior. The rather low steady ... ~To whom requests for reprints should be addressed, at the Laboratory of Pharma ceutical Chemistry, National ...... As anticipated

May 15, 2008 - hamster, and human cells to rBBX-01 (EC50 assay .... avastin; Gem/Dox, generic gemcitabine + pegylated liposomal doxorubicin; HKI-272, ...

would experience grade 3 or 4 toxicity, and thus to define a dose suitable for broad phase II evaluation. ...... (D-19466; lobaplatin) admin istered daily for 5 days.

Mar 15, 2008 - cycle of therapy was 805/ul and the median platelet nadir was 48,000/ul. Other toxic .... This was achieved using a Waters model 510 pump and ...

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 2008;7(9):2955-66. 44.

Departments of Pediatric Hematology/Oncology, State University of. New York Upstate Medical University, .... Downloaded from ..... Neuro-Oncology, 4: 102–108, 2002. 5. .... Bernstein, M. L. WR-2721 (amifostine) infusion in patients with Ew-.

Biochemistry and Pharmacy, School of Medicine, Texas Tech University Health. Sciences ... Current affiliation for A.S. Yang: Hematology/Oncology, Jazz Pharmaceuticals, ... and Human Services and the precepts of the Helsinki Declaration.

Apr 1, 1994 - nitrogen is believed to be the mechanism ... Doses of sodium phenylacetate to be infused over 30 min to 2 h were prepared in 150 ml .... posed of two pumps (305 and 306), an 805 manometric module, an 811C dynamic mixer ...

S. G. E., R. D., C. S., D. D. V. H., E. K. R.]; Brooke Army Medical. Center, Fort Sam ... 1 Supported in part by Ilex Oncology Inc., NIH Grant CA54174 to The.

Apr 9, 2017 - and renal function (defined as calculated creatinine clearance. 50 ml/minutes ..... the presence of the cisplatin analog nedaplatin, potentially ex-.

Val and 5-methylbenzoic acid form the lateral chain. The cycled region ...... (M)/prednisone (P) in men with androgen independent prostate cancer. J Clin Oncol ...

POH was formulated in soft gelatin capsules con- .... Drug Formulation. ... phase I design. .... No significant problems with myelosuppression were seen. Grade 1 ...

Oct 15, 2008 - Doxorubicin and trabectedin pharmacokinetics were not altered .... hematologic drug-related effects, and creatinine phosphokinase eleva-.

limiting toxicity; MTD, maximum-tolerated dose; ULN, upper limits of normal; ANC, absolute neutrophil count; EOI, end of infusion; BSA, body surface area; HSR, ...

feasibility, toxicity, and pharmacokinetics of an escalating dose of docetaxel when ...... This contrasts with the nonlinear pharmacokinetic profile of paclitaxel (20).

(/')determined the human pharmacokinetics of the drug on a. 6-h infusion ..... dexamethasone, and/or aminophylline were required to treat the reactions.

ovarian carcinoma malignant ascites. In brief,. 10” cells of the xenograft were .... had ovarian carcinoma. Of the remaining seven patients, two had sarcoma, one.

Apr 9, 2017 - mg/m2 increments, with intrapatient dose escalation permit- ted. Lymphocyte ... limiting toxicity of oral 5-FU given with the DPD-inactivator eniluracil on an .... required. A performance status (Cancer and Leukemia Group B) of.

liver function tests was indistinguishable from that described in patients with normal liver function .... cally based on the most abnormal pretreatment hepatic function test. Patients with serum ..... R. H., Hall, T. L., Crampton. S. L., and Swenber

2Supported by the Wayne State University Ben Kasle Fund for Cancer Research ..... Lacroix, A., and Lippman, M. E. Binding of retinoids to human breast cancer.

Stevens, S. J. Lee, D. A. Lowenthal, I. Haines, T. D. Walsh,. L. Baltzer ..... potential antitumor agents: a selective screening study. Cancer Treat. Rep.,. 62:45-74 ...

Other eligibility criteria included a prior platinum-containing chemotherapy, a GOG performance status. 2, and a cardiac ejection fraction (LVEF). 45%. Patients.

Feb 9, 2009 - with irinotecan hydrochloride (CPT-11) and nedaplatin ... hydrochloride and nedaplatin for cervical squamous cell .... DLT was defined as.